Elite in Febrile Neutropenia

Christian Berthou

UMR CNRS 6521 CEMCA, 6 Avenue Victor Le Gorgeu, 
Brest, FR 
Elite in Febrile Neutropenia
UMR CNRS 6521 CEMCA, 6 Avenue Victor Le Gorgeu, 
Brest, FR 
OverviewLocationsClinical Research

Overview

Christian Berthou practices in Brest, France. Mr. Berthou is rated as an Elite expert by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Febrile Neutropenia, Agranulocytosis, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Febrile Neutropenia.

Gender
Male

Locations

UMR CNRS 6521 CEMCA, 6 Avenue Victor Le Gorgeu, Brest, 29238, France
Other Locations
Nancy, France
Limoges, France
Bordeaux, France
Nantes, France
Lille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Identification of Genetic Factors Predisposing to Dysglobulinemia
Identification of Genetic Factors Predisposing to Dysglobulinemia
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Genetic
Study Phase: Not Applicable
A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q
A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Drug
Study Drug: EPREX Erythropoietin
Study Phase: Phase 3
A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Drugs: Decitabine, Hydroxyurea
Study Phase: Phase 3
View 2 Less Clinical Trials

96 Total Publications

MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.
MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.
Journal: Melanoma research
Published: February 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Berthou's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile